| Crystal structure of the mammalian MDC1 FHA domain complexed with CHK2 pThr68 peptide | |
Heteromer
Q5PSV9; | 66-73 | 100 | |
|
| Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase | | homo-2-mer | 89-501 | 99.74 | |
|
| Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase | | homo-2-mer | 92-501 | 99.73 | |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 210-515 | 100.0 | 2×HAU; 2×NO3; 2×CL; 14×EDO; |
|
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | | homo-2-mer | 210-513 | 100.0 | 2×NO3; 18×EDO; 2×A9U; 2×CL; |
|
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | | homo-2-mer | 210-513 | 100.0 | 2×A9T; 2×NO3; 6×EDO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 210-513 | 100.0 | 2×NO3; 2×WVI; 6×EDO; 2×CL; |
|
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | | homo-2-mer | 210-513 | 100.0 | 2×NO3; 2×RU5; 2×EDO; |
|
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | | homo-2-mer | 211-513 | 100.0 | 2×NO3; 2×RU9; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 210-512 | 100.0 | 6×EDO; 2×Z0O; 2×NO3; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 210-512 | 100.0 | 2×H3R; 2×NO3; 4×EDO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 210-512 | 100.0 | 2×P3J; 2×NO3; 2×EDO; 2×CL; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 211-513 | 100.0 | 2×Z2M; 2×NO3; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | homo-2-mer | 211-513 | 100.0 | 2×RQQ; 2×NO3; 6×EDO; |
|
| Crystal Structure of Chk2 in complex with an inhibitor | | homo-2-mer | 211-512 | 100.0 | 2×XBJ; 2×MG; 4×NO3; |
|
| Structure of a small molecule inhibitor with the kinase domain of Chk2 | | homo-2-mer | 211-512 | 100.0 | 2×LWH; 2×NO3; |
|
| Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531 | | homo-2-mer | 210-510 | 100.0 | 2×YCF; 2×MG; 2×NO3; |
|
| Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibi… | | homo-2-mer | 210-510 | 100.0 | 2×D1A; 2×MG; 2×NO3; 4×EDO; |
|
| Crystal structure of checkpoint kinase 2 in complex with PV788 | | homo-2-mer | 210-510 | 100.0 | 2×NXP; 2×NO3; |
|
| Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322 | | homo-2-mer | 211-510 | 100.0 | 2×YIQ; 2×NO3; |
|
| Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115 | | homo-2-mer | 211-510 | 100.0 | 2×UPX; 2×NO3; |
|
| Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352 | | homo-2-mer | 210-509 | 100.0 | 2×YIR; 2×NO3; |
|
| Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor | | homo-2-mer | 211-510 | 100.0 | 2×YIT; 2×NO3; |
|
| Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976 | | homo-2-mer | 211-510 | 99.64 | 2×HCW; 2×NO3; |
|
| Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533 | | homo-2-mer | 211-510 | 100.0 | 2×XK9; |
|
| Crystal structure of human Chk2 in complex with ADP | | homo-2-mer | 209-504 | 99.64 | 2×CL; 4×MG; 2×NO3; 2×ADP; |
|
| Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2 | | homo-2-mer | 211-503 | 100.0 | 2×B4W; |
|
| Crystal structure of human Chk2 in complex with debromohymenialdisine | | homo-2-mer | 212-503 | 100.0 | 2×MG; 2×NO3; 2×DBQ; |
|
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | | monomer | 209-512 | 99.65 | 1×WTJ; 2×NO3; 4×EDO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | monomer | 210-513 | 100.0 | 1×NO3; 9×EDO; 1×ODO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | monomer | 210-513 | 100.0 | 1×NO3; 4×EDO; 1×CWS; |
|
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | | monomer | 210-512 | 100.0 | 1×WTI; 2×NO3; 2×EDO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | monomer | 210-512 | 100.0 | 1×NO3; 7×EDO; 1×VFB; 1×CL; |
|
| Crystal structure of Chk2 in complex with an inhibitor | | monomer | 210-512 | 100.0 | 1×ZZK; 1×NO3; 3×EDO; |
|
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | | monomer | 210-512 | 100.0 | 1×ODH; 1×NO3; 1×CL; 1×EDO; |
|
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | | monomer | 211-512 | 100.0 | 1×VGM; 1×NO3; |
|
| Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor | | monomer | 210-510 | 100.0 | 1×ZAT; 1×NO3; |
|
| FHA domain from human Chk2 kinase in complex with a synthetic phosphopeptide | | monomer | 92-207 | 100 | |
|